REWIND METABOLIC DISEASE
METABOLIC MANAGERS
Junevity targets upstream regulators of complex metabolic disease.
These regulators work through known pharmacological pathways leading to disease reversal.
breakthrough science
Junevity’s founders spent six years at UCSF creating a next-generation approach to identifying regulators of complex disease.
JUNEVITY REWIND™ DISCOVERY PLATFORM
Junevity REWIND finds novel targets for metabolic disease based on human disease data and known pharmacological pathways.
It builds on innovations in genomics, machine learning, CRISPR, and regulatory biology.
THERAPEUTIC DEVELOPMENT
Junevity is advancing therapeutic programs for serious metabolic diseases that together affect over one billion people worldwide.
We imagine a world where metabolic-related diseases are no longer the leading cause of death.
